An update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia

作者：Bee P C^*; Gan G G; Tai Y T; Haris A R; Chin E; Veera S N

来源：Singapore Medical Journal, 2012, 53(1): 57-61.

• chronic myeloid leukaemia
• chronic phase
• imatinib mesylate
• major cytogenetic response
• overall survival

INTRODUCTION The introduction of imatinib mesylate in 1998 has changed the management of chronic myeloid leukaemia. It is now the first-line therapy for newly diagnosed chronic myeloid leukaemia patients worldwide. However, its long-term survival benefit still needs to be established in clinical setting among Asian patients. %26lt;br%26gt;METHODS All chronic myeloid leukaemia patients in the chronic phase who were on imatinib mesylate therapy were retrospectively reviewed. Data was collected through a review of case notes, which was then processed, managed and analysed. %26lt;br%26gt;RESULTS A total of 44 patients were included in the study. The cumulative rates of complete haematological response, major cytogenetic response and major molecular response were 93.2%, 75.0% and 34.2%, respectively. The overall survival and event-free survival at five years were 86.0% and 84.9%, respectively. 31.8% of the patients developed anaemia, 29.5% neutropenia and 27.3% thrombocytopenia. A total of 43.2% of patients developed non-haematological side effects. Higher dosage (%26gt; 600 mg) and smaller body size (%26lt; 60 kg) were risk factors for haematological side effects. Patients with major cytogenetic response and absence of thrombocytopenia had better survival. %26lt;br%26gt;CONCLUSION The majority of our chronic myeloid leukaemia patients did well with imatinib therapy. The adverse effects in our patients were tolerable, and no patient had to stop treatment permanently.

• 出版日期2012-1